Comments to FDA: Postmarketing Safety Reports for Human Drug and Biological Products Share page: Docket Number: FDA-2008-N-0334 Comments regarding a proposed rule on electronic submission requirements for postmarketing safety reports for human drug and biological products. Download Document Issues: OTC Medicines Related Posts Comments Comments Regarding Control of Nitrosamine Impurities in Human Drugs Dec 20, 2024 Press Releases and Statements Rates for Teen Abuse of OTC Cough/Cold Medication Remains Low According to NIDA Survey Dec 18, 2024 Pediatric Cough/Cold Dosing